Shanghai Kehua Bio-engineering (002022.SZ) announced that it will undertake the project of Shaanxi High-performance Diagnostic Medical Instruments Innovation Center...
Asia Vets Finance App, Shanghai Kehua Bio-engineering (002022.SZ) announced that it will undertake the project of Shaanxi High-performance Diagnostic Medical Instruments Innovation Center, in line with the industrial focus on the high-end and intelligent development of medical instruments, integrating various advantageous resources to enhance comprehensive competitiveness. The Company's controlling subsidiary, Xi'an Tianlong Technology Co., Ltd. (referred to as "Xi'an Tianlong" in short), and its wholly-owned subsidiary, Xi'an Huawei Technology Co., Ltd. (referred to as "Xi'an Huawei" in short), as well as the Company's wholly-owned subsidiary, Kehua (Xi'an) Bioengineering Co., Ltd. (referred to as "Xi'an Kehua" in short), plan to jointly invest 68 million yuan of their own funds to establish Shaanxi High-performance Diagnostic Technology Co., Ltd. (subject to registration and approval by the market supervision department).
This investment to establish a subsidiary aims to undertake the project of Shaanxi High-performance Diagnostic Medical Instruments Innovation Center, aligning with the industry's focus on high-end and intelligent development of medical instruments, integrating various advantageous resources to enhance comprehensive competitiveness. This investment is in line with the company's global strategy and is beneficial for the company's long-term operational development.
